Skip to main content

08-20-2021 | Ultra-rapid lispro | News


FDA approves ultra-rapid lispro for use in pumps

Eleanor McDermid

medwireNews: Ultra-rapid lispro may now be used in insulin pumps by people with type 1 diabetes in the USA following FDA approval.

This decision in based on the results of the PRONTO-PUMP-2 trial, in which pump users had significantly lower postprandial glucose levels with ultra-rapid lispro versus lispro, and spent significantly less time in hypoglycemia overall.

The alterations to the medication label also include the warning that insulin pump or infusion set malfunction can lead rapidly to ketoacidosis.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

Addressing suicide risk in diabetes

07-14-2021 | Mental health | Feature | Article

Suicide in diabetes: An important but under-recorded problem

How frequent are suicide deaths in people with diabetes, and can the data be trusted?

07-14-2021 | Mental health | Feature | Article

Risk for suicidal ideation: Who, when, and why?

What makes some people more likely than others to have suicidal thoughts? We outline the risk factors and circumstances that can play a role.

07-14-2021 | Mental health | Feature | Article

Creating a safety net: How doctors can help suicidal patients

Screening, emergency protocols, and person-centered care – just some of the ways healthcare professionals can identify and support people at increased risk for suicide. Click through for more.

Suicide risk in diabetes: Why doctors may hesitate to screen, but should not

ESC Congress 2021 coverage

27 – 30 August: Browse all of the latest coverage